Client: A Healthcare Organization
Challenge:
A healthcare organization sought to assess the COVID-19 pandemic’s impact on NHS cancer screening performance. They aimed to determine how disruptions affected cancer morbidity and mortality rates, posing significant challenges for public health management.
Solution Provided by Clevidence:
Clevidence was engaged to conduct a comprehensive study involving several key steps:
- Data Collection and Analysis:
We analyzed publicly available data on NHS performance indicators, comparing pre-pandemic and pandemic periods, specifically the number of eligible individuals screened for breast, cervical, and colorectal cancers. - Modeling Hypothetical Scenarios:
We applied an exponential smoothing algorithm to pre-pandemic data to project scenarios without pandemic disruptions, comparing these to actual data from the pandemic. - Markov Model Development:
We developed a Markov model to estimate potential years of life lost (YLL) due to reduced cancer screenings and treatment delays, highlighting long-term consequences, including the loss of thousands of years of life within the population. - Comprehensive Reporting:
Our findings were compiled into a report outlining decreases in screening rates and their implications for cancer morbidity and mortality.
Results:
The study provided valuable insights into the effects of the COVID-19 pandemic on NHS cancer screening, emphasizing the importance of regular screenings and long-term impacts on patient health, including significant YLL.
Conclusion:
Through rigorous analysis and reporting, Clevidence enabled the healthcare organization to understand the implications of pandemic-related disruptions on cancer screening.
